FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891294583> ?p ?o ?g. }

• W2891294583 endingPage "1417" @default.
• W2891294583 startingPage "1410" @default.
• W2891294583 abstract "BACKGROUNDThe multinational AMBITION study demonstrated a 50% risk reduction in time to first clinical failure event (TtCF, a composite of death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) in treatment-naive Functional Class II and III PAH patients initiated on combination therapy (ambrisentan and tadalafil) vs monotherapy. A post-hoc analysis of AMBITION data by risk stratification, as determined by baseline REVEAL risk score, was undertaken to better assess the impact of combination therapy.METHODSPatients were randomized 2:1:1 to initial combination therapy with ambrisentan 10 mg plus tadalafil 40 mg vs either drug plus placebo, respectively. Baseline REVEAL risk scores in the 605 patients were grouped by low, intermediate, or high risk. Adjudicated outcomes (TtCF and post-hoc composite end-point of time to first PAH hospitalization or death) were assessed by risk group and treatment assignment.RESULTSAt baseline, risk groups were similarly represented across treatment assignments as low (16%), intermediate (46%), and high (38%) risk. Greater risk was associated with worse outcome. At each level of risk, patients on combination therapy had significantly fewer TtCF or PAH hospitalization/death events relative to those on monotherapy, and discontinuations due to adverse events were not higher on combination therapy.CONCLUSIONSThis post-hoc analysis comparing outcomes by REVEAL risk group has shown that, at all levels of risk, patients enrolled in AMBITION receiving initial combination therapy have superior outcomes and, even in those assessed as low risk, initial combination therapy was clinically beneficial. The multinational AMBITION study demonstrated a 50% risk reduction in time to first clinical failure event (TtCF, a composite of death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) in treatment-naive Functional Class II and III PAH patients initiated on combination therapy (ambrisentan and tadalafil) vs monotherapy. A post-hoc analysis of AMBITION data by risk stratification, as determined by baseline REVEAL risk score, was undertaken to better assess the impact of combination therapy. Patients were randomized 2:1:1 to initial combination therapy with ambrisentan 10 mg plus tadalafil 40 mg vs either drug plus placebo, respectively. Baseline REVEAL risk scores in the 605 patients were grouped by low, intermediate, or high risk. Adjudicated outcomes (TtCF and post-hoc composite end-point of time to first PAH hospitalization or death) were assessed by risk group and treatment assignment. At baseline, risk groups were similarly represented across treatment assignments as low (16%), intermediate (46%), and high (38%) risk. Greater risk was associated with worse outcome. At each level of risk, patients on combination therapy had significantly fewer TtCF or PAH hospitalization/death events relative to those on monotherapy, and discontinuations due to adverse events were not higher on combination therapy. This post-hoc analysis comparing outcomes by REVEAL risk group has shown that, at all levels of risk, patients enrolled in AMBITION receiving initial combination therapy have superior outcomes and, even in those assessed as low risk, initial combination therapy was clinically beneficial." @default.
• W2891294583 created "2018-09-27" @default.
• W2891294583 creator A5002527277 @default.
• W2891294583 creator A5006434846 @default.
• W2891294583 creator A5009975917 @default.
• W2891294583 creator A5020503955 @default.
• W2891294583 creator A5021047743 @default.
• W2891294583 creator A5082243480 @default.
• W2891294583 creator A5087086652 @default.
• W2891294583 date "2018-12-01" @default.
• W2891294583 modified "2023-10-18" @default.
• W2891294583 title "Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score" @default.
• W2891294583 cites W1866413456 @default.
• W2891294583 cites W1984693219 @default.
• W2891294583 cites W2049971329 @default.
• W2891294583 cites W2054663847 @default.
• W2891294583 cites W2096223780 @default.
• W2891294583 cites W2112229901 @default.
• W2891294583 cites W2114374604 @default.
• W2891294583 cites W2114863766 @default.
• W2891294583 cites W2117339256 @default.
• W2891294583 cites W2140319297 @default.
• W2891294583 cites W2141987653 @default.
• W2891294583 cites W2142743112 @default.
• W2891294583 cites W2146177859 @default.
• W2891294583 cites W2161370807 @default.
• W2891294583 cites W2165248837 @default.
• W2891294583 cites W2167360168 @default.
• W2891294583 cites W2743897368 @default.
• W2891294583 cites W2744074505 @default.
• W2891294583 doi "https://doi.org/10.1016/j.healun.2018.07.001" @default.
• W2891294583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30209017" @default.
• W2891294583 hasPublicationYear "2018" @default.
• W2891294583 type Work @default.
• W2891294583 sameAs 2891294583 @default.
• W2891294583 citedByCount "12" @default.
• W2891294583 countsByYear W28912945832019 @default.
• W2891294583 countsByYear W28912945832020 @default.
• W2891294583 countsByYear W28912945832021 @default.
• W2891294583 countsByYear W28912945832022 @default.
• W2891294583 countsByYear W28912945832023 @default.
• W2891294583 crossrefType "journal-article" @default.
• W2891294583 hasAuthorship W2891294583A5002527277 @default.
• W2891294583 hasAuthorship W2891294583A5006434846 @default.
• W2891294583 hasAuthorship W2891294583A5009975917 @default.
• W2891294583 hasAuthorship W2891294583A5020503955 @default.
• W2891294583 hasAuthorship W2891294583A5021047743 @default.
• W2891294583 hasAuthorship W2891294583A5082243480 @default.
• W2891294583 hasAuthorship W2891294583A5087086652 @default.
• W2891294583 hasBestOaLocation W28912945831 @default.
• W2891294583 hasConcept C126322002 @default.
• W2891294583 hasConcept C141071460 @default.
• W2891294583 hasConcept C142724271 @default.
• W2891294583 hasConcept C144980905 @default.
• W2891294583 hasConcept C168563851 @default.
• W2891294583 hasConcept C170493617 @default.
• W2891294583 hasConcept C197934379 @default.
• W2891294583 hasConcept C204787440 @default.
• W2891294583 hasConcept C27081682 @default.
• W2891294583 hasConcept C2776999253 @default.
• W2891294583 hasConcept C2779929075 @default.
• W2891294583 hasConcept C2780263000 @default.
• W2891294583 hasConcept C2780816001 @default.
• W2891294583 hasConcept C2781109936 @default.
• W2891294583 hasConcept C44249647 @default.
• W2891294583 hasConcept C67761136 @default.
• W2891294583 hasConcept C71924100 @default.
• W2891294583 hasConcept C82789193 @default.
• W2891294583 hasConceptScore W2891294583C126322002 @default.
• W2891294583 hasConceptScore W2891294583C141071460 @default.
• W2891294583 hasConceptScore W2891294583C142724271 @default.
• W2891294583 hasConceptScore W2891294583C144980905 @default.
• W2891294583 hasConceptScore W2891294583C168563851 @default.
• W2891294583 hasConceptScore W2891294583C170493617 @default.
• W2891294583 hasConceptScore W2891294583C197934379 @default.
• W2891294583 hasConceptScore W2891294583C204787440 @default.
• W2891294583 hasConceptScore W2891294583C27081682 @default.
• W2891294583 hasConceptScore W2891294583C2776999253 @default.
• W2891294583 hasConceptScore W2891294583C2779929075 @default.
• W2891294583 hasConceptScore W2891294583C2780263000 @default.
• W2891294583 hasConceptScore W2891294583C2780816001 @default.
• W2891294583 hasConceptScore W2891294583C2781109936 @default.
• W2891294583 hasConceptScore W2891294583C44249647 @default.
• W2891294583 hasConceptScore W2891294583C67761136 @default.
• W2891294583 hasConceptScore W2891294583C71924100 @default.
• W2891294583 hasConceptScore W2891294583C82789193 @default.
• W2891294583 hasFunder F4320307773 @default.
• W2891294583 hasFunder F4320308573 @default.
• W2891294583 hasIssue "12" @default.
• W2891294583 hasLocation W28912945831 @default.
• W2891294583 hasLocation W28912945832 @default.
• W2891294583 hasLocation W28912945833 @default.
• W2891294583 hasOpenAccess W2891294583 @default.
• W2891294583 hasPrimaryLocation W28912945831 @default.
• W2891294583 hasRelatedWork W1981931011 @default.
• W2891294583 hasRelatedWork W2016513370 @default.
• W2891294583 hasRelatedWork W2780740273 @default.
• W2891294583 hasRelatedWork W2809522867 @default.

• next